The phosphatidylinositol 3-kinases (PI3Ks) are known regulators of cellular growth and proliferation. It has recently been reported that somatic mutations within the PI3K subunit p110α (PIK3CA) are present in human colorectal and other cancers. Here we show that thirteen of fifty-three breast cancers (25%) contain somatic mutations in PIK3CA, with the majority of mutations located in the kinase domain. These results demonstrate that PIK3CA is the most mutated oncogene in breast cancer and support a role for PIK3CA in epithelial carcinogenesis.
INTRODUCTION
PI3Ks are lipid kinases that regulate diverse cellular signaling pathways and are often altered in human malignancies. 1 Studies suggest important roles for PI3K signaling in the regulation of cell growth, cell migration, epithelial to mesenchymal transition, alternative splicing events, and maintenance of tissue morphologies. [2] [3] [4] [5] [6] In breast malignancies, changes in PI3K activity have also been associated with an increased resistance to chemotherapeutic and radiation therapies. [7] [8] [9] [10] Although deregulation of PI3Ks has been previously documented in tumorigenesis, 11 the presence of somatic point mutations within this family of genes in human cancers has only recently been demonstrated. 12 In this landmark study, a high frequency of PIK3CA mutations was found in colorectal and other human cancers. However, of the twelve human breast cancers analyzed in this study only one (8%) contained a mutation, suggesting that mutational activation of this gene in breast cancers is an uncommon event. Due to the small sample size of breast cancers used in this study, we expanded this analysis using forty-one primary invasive breast cancers and twelve human breast cancer cell lines. In addition, we examined the relationship of PIK3CA mutational status with known determinants of breast cancer prognosis and therapy.
MATERIALS AND METHODS
Cell Lines and Primary Samples. Cell lines and cell line genomic DNA were purchased from American Type Culture Collection (ATCC, Manassas, VA). Primary samples were obtained as paraffin embedded slides from archival materials and were coded and kept anonymous according to procedures approved by the Johns Hopkins Institutional Review Board.
Genomic DNA Preparation and Sequencing. Primary human invasive breast cancers and adjacent normal tissue were micro-dissected and genomic DNA prepared as previously described. 13 DNA from tumor and normal tissue was polymerase chain reaction (PCR) amplified, and directly sequenced as previously described. 12 Genomic sequencing was performed using primers described by Samuels et al. 12 In some cases, only a small amount of DNA could be recovered from microdissected samples. Therefore, a nested or hemi-nested PCR approach was used with the following primers: Exon 1 template PCR; forward 5' CTCCACGACCATCATCAGG 3' and reverse 5' GAT-TACGAAGGTATTGGTTTAGACAG 3'. Exon 1 hemi-nested PCR; forward 5' ACTTGATGCC-CCCAAGAATC 3' and reverse from template PCR. Exon 1 sequencing primers were 5' CTGCTT-CTTGAGTAACACTTACG 3' and 5' CCCCCTCCATCAACTTCTTC 3'. Exon 9 template PCR; forward 5' GATTGGTTCTTTCCTGTCTCTG 3' and reverse 5' CCACAAATATCAATTTACAA-CCATTG 3'. Exon 9 nested PCR; forward 5' TTGCTTTTTCTGTAAATCATCTGTG 3' and reverse 5' TATGGTAAAAACATGCTGAG 3'. Exon 9 sequencing primer was 5' TAAATCATCT-GTGAATCCAGAG 3'. Exon 20 was sequenced in two parts, exon 20-1 and 20-2. Primers for exon 20-1 template PCR were forward 5' TGACATTTGAGCAAAGACCTG 3' and reverse 5' GGATTGTGCAATTCCTATGC 3'. Exon 20-1 hemi-nested PCR; forward 5' TTACTTATAG-GTTTCAGGAG 3' and exon 20-1 template reverse primer. Exon 20-1 sequencing primer was 5' CCTATGCAATCGGTCTTTGC 3'. Primers for exon 20-2 template PCR were forward 5' TTTTCTCAATGATGCTTGGC 3' and reverse 5' GGGGATTTTTGTTTTGTTTTG 3'; exon 20-2 hemi-nested PCR; forward 5' TTGCATACATTCGAAAGACC 3' and exon 20-2 template reverse primer. Exon 20-2 sequencing primer was 5' TGGACTTAAGGCA-TAACATG 3'. All mutations were verified at least twice, as were the normal controls.
Immunohistochemistry Analysis. Immunohistochemistry for estrogen and progesterone receptors was done using a standardized laboratory protocol for formalin-fixed, paraffin-embedded tissue sections on the Ventana Benchmark XT (Ventana, Tuscon, Arizona). For Estrogen receptor, the 6F11 monoclonal antibody (Novacastra, Newcastle upon Tyne, UK) was used at a dilution of 1:50. For Progesterone receptor, the PGR636 monoclonal antibody (Dako, Carpinteria, CA) was used at a dilution of 1:60. Only nuclear labeling was scored as positive. Normal breast tissue surrounding the tumors served as internal controls. For Her-2/neu status, we used the Dako Herceptest Kit (Dako, Carpinteria, CA) as per the manufacturers instructions for formalin-fixed, paraffin-embedded tissue sections. Tumors were scored as negative (0 or 1+), weak positive (2+), or strong positive (3+) based upon the intensity and extent of membranous labeling. 
RESULTS
Due to the scarce amount of DNA derived from these samples, we chose to examine only exons 1, 9 and 20 as these exons have been shown to harbor >91% of the somatic mutations found in colorectal and other cancers. 12 Exon 1 of the PIK3CA gene encodes for the p85 binding domain, while exons 9 and 20 encode for the helical and kinase domains respectively. The frequency of observed mutations is shown in Table 1 . Of the forty-one primary breast cancers used in our study, nine contained somatic missense mutations. Two of these mutations were found in exon 1, one mutation was present in exon 9, and the remaining mutations were located within exon 20. In all cases where mutations were demonstrated, DNA from adjacent normal mammary or lymphoid tissue revealed the presence of wild-type sequence only, confirming that the mutations were indeed somatic. In addition to our primary samples, we also sequenced genomic DNA from twelve well established human breast cancer cell lines (Table 2 ). This analysis demonstrated that four out of twelve cell lines contained PIK3CA mutations (30%), half of which were in exon 9 and half in exon 20. Taken together, our combined analyses show that PIK3CA mutations are present in 25% of human breast cancers.
The status of estrogen and progesterone receptors (ER/PR), as well as the presence or absence of Her-2/neu amplification, are independent determinants of breast cancer prognosis, as well as predictors of response to targeted therapy. 14, 15 To determine the relationship between PIK3CA mutational status with these known determinants, we analyzed our primary samples for receptor status using immunohistochemical methods and fluorescence in situ hybridization for Her-2/neu when indicated. As seen in Table 1 , there was no correlation between PIK3CA mutations and the presence or absence of ER/PR labeling. In a similar manner, Her-2/ neu expression status did not correlate with the presence or absence of PIK3CA mutations. Finally, the nodal status and histologic type of breast cancers (ductal versus lobular) used in our study suggest that PIK3CA mutations are not exclusive to any specific subgroup of breast cancer. These data suggest that PIK3CA mutations affect signaling pathways independent from those of ER/PR and Her-2/neu.
DISCUSSION
The spectrum of mutations found in our study is similar to the analysis by Samuels et al., but there are some important differences. In their study, forty-three exon 9 and twenty-seven exon 20 mutations were found suggesting exon 9 mutations are the most common PIK3CA mutations in colorectal and other cancers. In contrast, we found only three mutations within exon 9, but uncovered eight exon 20 mutations within our fifty-three samples, suggesting that exon 20 mutations predominate in human breast cancers. In addition, three novel somatic mutations were discovered including two in exon 1 and one in exon 20 (Table 1 and Fig. 1 ). It should be noted that no truncating mutations were found and all of the mutations were heterozygous consistent with previous reports describing the oncogenic nature of these mutations. Our data expand the work of Samuels et al. by providing a more comprehensive analysis of PIK3CA mutations in human breast cancers. The higher percentage of mutations found in our study likely stems from the larger sample size that we used. To our knowledge, these data place the PIK3CA gene as the most mutated oncogene in human breast cancer. In addition, it appears that PIK3CA mutational status does not segregate with ER/PR, Her-2/neu or nodal status in primary invasive breast cancers. It will therefore be of interest to determine in larger randomized trials whether PIK3CA mutations can be used as independent markers for risk and prognosis. More importantly, this work allows for the development of therapies specifically targeted towards the substantial number of women with breast cancers harboring these mutations. Mutations are shown as nucleotide change followed by amino acid change.
